Pentixapharm Holding AG Logo

Pentixapharm Holding AG

Develops radiopharmaceuticals for diagnosing and treating oncology and adrenal disorders.

PTP | F

Overview

Corporate Details

ISIN(s):
DE000A383RV0 (+1 more)
LEI:
3912005VBOVXNDXEQZ36
Country:
Germany
Address:
Robert-Rössle-Straße, 10, 13125 Berlin
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Pentixapharm Holding AG is a clinical-stage radiopharmaceutical development company that creates innovative, first-in-class compounds for both diagnostic and therapeutic applications. The company's pipeline primarily targets unmet medical needs in oncology, including hemato-oncology and solid tumors, as well as adrenal disorders. Key assets include two Phase III-ready drug candidates and a well-researched CXCR4-targeting compound. With a strong research and development focus, Pentixapharm has administered its compounds to over 2,000 patients in clinical settings.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-16 15:19
Director's Dealing
Pentixapharm Holding AG: Eckert Wagniskapital und Fruhphasenfinanzierung GmbH, …
English 6.1 KB
2025-09-15 11:49
Director's Dealing
Pentixapharm Holding AG: Dr. Andreas Eckert, buy
English 5.8 KB
2025-08-06 00:00
Interim Report
Half-yearly financial report 2025
English 723.4 KB
2025-07-24 14:04
Report Publication Announcement
English 3.9 KB
2025-05-27 09:43
Regulatory News Service
Pentixapharm Holding AG: Pentixapharm outlines new clinical development strategy
English 10.0 KB
2025-05-08 00:00
Quarterly Report
Q1 statement / Q1 financial report 2025
English 479.2 KB
2025-04-26 16:00
Report Publication Announcement
English 3.8 KB
2025-04-25 00:00
Annual Report
Annual financial report 2024
English 2.3 MB
2025-04-24 14:00
Regulatory News Service
Pentixapharm Signs Contract Manufacturing Agreement for Yttrium-90-based Pentix…
English 8.8 KB
2025-04-17 15:05
Pre-Annual General Meeting Information
Pentixapharm Holding AG: Bekanntmachung der Einberufung zur Hauptversammlung am…
German 88.5 KB
2025-04-15 08:17
Report Publication Announcement
Pentixapharm Holding AG Releases Financial Results for 2024 and Announces Guida…
English 6.4 KB
2025-03-19 13:20
Report Publication Announcement
English 3.9 KB
2025-03-18 13:20
Report Publication Announcement
English 3.9 KB
2025-03-04 14:38
Board/Management Information
Changes in the Supervisory Board and Management Board of Pentixapharm Holding AG
English 6.4 KB
2025-03-03 14:38
Board/Management Information
Changes in the Supervisory Board and Management Board of Pentixapharm Holding AG
English 6.4 KB

Automate Your Workflow. Get a real-time feed of all Pentixapharm Holding AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Pentixapharm Holding AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
2cureX AB Logo
Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.
Sweden 2CUREX
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom 4BB
4SC AG Logo
Developing small-molecule epigenetic drugs for high-need cancer indications.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using its OMV platform, with a lead pneumococcal candidate.
Sweden ABERA
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom ABDX
ABIONYX Pharma Logo
Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.
France ABNX
Abliva Logo
Develops clinical-stage medicines for rare primary mitochondrial diseases to restore cell function.
Sweden ABLI
AB Science Logo
Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.
France AB
Access Bio, Inc. Logo
Develops and manufactures rapid diagnostic tests for infectious diseases for global health.
United States of America 950130
Active Biotech Logo
Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.
Sweden ACTI

Talk to a Data Expert

Have a question? We'll get back to you promptly.